167 related articles for article (PubMed ID: 19145098)
1. Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients.
Bellos F; Mahlknecht U
Onkologie; 2008 Nov; 31(11):629-33. PubMed ID: 19145098
[TBL] [Abstract][Full Text] [Related]
2. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
Bug G; Ritter M; Wassmann B; Schoch C; Heinzel T; Schwarz K; Romanski A; Kramer OH; Kampfmann M; Hoelzer D; Neubauer A; Ruthardt M; Ottmann OG
Cancer; 2005 Dec; 104(12):2717-25. PubMed ID: 16294345
[TBL] [Abstract][Full Text] [Related]
4. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.
Kuendgen A; Schmid M; Schlenk R; Knipp S; Hildebrandt B; Steidl C; Germing U; Haas R; Dohner H; Gattermann N
Cancer; 2006 Jan; 106(1):112-9. PubMed ID: 16323176
[TBL] [Abstract][Full Text] [Related]
5. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia.
Raffoux E; Chaibi P; Dombret H; Degos L
Haematologica; 2005 Jul; 90(7):986-8. PubMed ID: 15996941
[TBL] [Abstract][Full Text] [Related]
6. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.
Pilatrino C; Cilloni D; Messa E; Morotti A; Giugliano E; Pautasso M; Familiari U; Cappia S; Pelicci PG; Lo Coco F; Saglio G; Guerrasio A
Cancer; 2005 Jul; 104(1):101-9. PubMed ID: 15895376
[TBL] [Abstract][Full Text] [Related]
7. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia.
Cimino G; Lo-Coco F; Fenu S; Travaglini L; Finolezzi E; Mancini M; Nanni M; Careddu A; Fazi F; Padula F; Fiorini R; Spiriti MA; Petti MC; Venditti A; Amadori S; Mandelli F; Pelicci PG; Nervi C
Cancer Res; 2006 Sep; 66(17):8903-11. PubMed ID: 16951208
[TBL] [Abstract][Full Text] [Related]
8. Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates.
Qi H; Ratnam M
Cancer Res; 2006 Jun; 66(11):5875-82. PubMed ID: 16740727
[TBL] [Abstract][Full Text] [Related]
9. Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment.
Fredly H; Reikvam H; Gjertsen BT; Bruserud O
Am J Hematol; 2012 Apr; 87(4):368-76. PubMed ID: 22374841
[TBL] [Abstract][Full Text] [Related]
10. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid.
Kuendgen A; Strupp C; Aivado M; Bernhardt A; Hildebrandt B; Haas R; Germing U; Gattermann N
Blood; 2004 Sep; 104(5):1266-9. PubMed ID: 15155466
[TBL] [Abstract][Full Text] [Related]
11. Clofibric acid: a potential therapeutic agent in AML and MDS.
Fenton SL; Drayson MT; Hewison M; Vickers E; Brown G; Bunce CM
Br J Haematol; 1999 May; 105(2):448-51. PubMed ID: 10233420
[TBL] [Abstract][Full Text] [Related]
12. A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid.
Ryningen A; Stapnes C; Lassalle P; Corbascio M; Gjertsen BT; Bruserud O
Leuk Res; 2009 Jun; 33(6):779-87. PubMed ID: 19007987
[TBL] [Abstract][Full Text] [Related]
13. A limited number of 5-azacitidine cycles can be effective treatment in MDS.
Müller-Thomas C; Schuster T; Peschel C; Götze KS
Ann Hematol; 2009 Mar; 88(3):213-9. PubMed ID: 18696067
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
[TBL] [Abstract][Full Text] [Related]
15. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
[TBL] [Abstract][Full Text] [Related]
16. [Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases].
Guan M; Chen SC; Ge CW
Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):919-22. PubMed ID: 19671296
[TBL] [Abstract][Full Text] [Related]
17. Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study.
Giagounidis AA; Haase S; Germing U; Schlegelberger B; Wilkens L; Büsche G; Kreipe HH; Wysk J; Grips KH; Grabenhorst U; Rothmann F; Lübbert M; Ganser A; Aivado M; Heinsch M; Aul C
Ann Hematol; 2005 Jun; 84(6):389-94. PubMed ID: 15785949
[TBL] [Abstract][Full Text] [Related]
18. DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy.
Grishina O; Schmoor C; Döhner K; Hackanson B; Lubrich B; May AM; Cieslik C; Müller MJ; Lübbert M
BMC Cancer; 2015 May; 15():430. PubMed ID: 26008690
[TBL] [Abstract][Full Text] [Related]
19. Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias.
Morgan MA; Reuter CW
Ann Hematol; 2006 Mar; 85(3):139-63. PubMed ID: 16391911
[TBL] [Abstract][Full Text] [Related]
20. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine.
Arana-Yi C; Block AW; Sait SN; Ford LA; Barcos M; Baer MR
Leuk Res; 2008 Jul; 32(7):1043-8. PubMed ID: 18093651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
